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Abstract: The aim of this study was to examine the burden of fungal disease in Norway, contributing
to a worldwide effort to improve awareness of the needs for better diagnosis and treatment of such
infections. We used national registers and actual data from the Departments of Microbiology from
2015 and estimated the incidence and/or prevalence of superficial, allergic and invasive fungal
disease using published reports on specific populations at risk. One in 6 Norwegians suffered from
fungal disease: Superficial skin infections (14.3%: 745,600) and recurrent vulvovaginal candidiasis in
fertile women (6%: 43,123) were estimated to be the most frequent infections. Allergic fungal lung
disease was estimated in 17,755 patients (341/100,000). Pneumocystis jirovecii was diagnosed in 262
patients (5/100,000), invasive candidiasis in 400 patients (7.7/100,000), invasive aspergillosis in 278
patients (5.3/100,000) and mucormycosis in 7 patients (0.1/100,000). Particular fungal infections
from certain geographic areas were not observed. Overall, 1.79% of the population was estimated
to be affected by serious fungal infections in Norway in 2015. Even though estimates for invasive
infections are small, the gravity of such infections combined with expected demographic changes in
the future emphasizes the need for better epidemiological data.
Keywords: epidemiology; fungal burden; allergic bronchopulmonary aspergillosis (ABPA); severe
asthma with fungal sensitization (SAFS); Pneumocystis; Candida; aspergillosis; mucorales; Norway
1. Introduction
Fungal diseases are common with variable morbidity ranging from a toenail infection causing
cosmetic worry to invasive disease with a relatively high mortality rate among infectious diseases.
The incidence of invasive fungal infections is highly dependent on patients with immunocompromised
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states. Therefore, societies where acquired immune deficiency syndrome (AIDS) and tuberculosis are
of major concern are in dire need of rapid and accurate diagnosis and availability of antifungal drugs
to acceptable prices.
In the western world, many report an increased incidence of invasive fungal infections, but
apart from candidemias, few epidemiological studies exist on other fungal infections [1,2]. Due to
improvement in the general health and medical care in this part of the world, we expect more
patients and in particular an increasing proportion of the elderly to live their life longer in an
immunocompromised state. Thus, the predicament is that fungal infections will become a bigger
problem in years ahead.
Estimates of the fungal burden in various countries have been made in order to increase awareness
of these diseases in the medical and political community. Due to lack of incidence and prevalence data
on fungal infections, estimates have been made based on extrapolation of data from known conditions
rendering the patient susceptible to these infections combined with actual data from publications in
smaller populations. In Norway, national surveillance of candidemia has been ongoing since 1991 [3–5].
No reports on the epidemiology of other fungal disease exist. In this study, we aim to estimate the
burden of fungal disease based on actual and estimated data from 2015.
2. Materials and Methods
Data on specific populations were obtained from national data registers concerning
(1) demography [6]; (2) chronic obstructive pulmonary disease (COPD) and tuberculosis [7];
(3) solid organ transplantation (SOT) [8], hematopoietic stem cell transplantation (HSCT) (personal
communication from Tobias Gedde-Dahl, Department of Hematology, Oslo University Hospital,
Oslo, Norway); (4) hematological and lung cancers [9]; (5) cystic fibrosis (CF) [10]; (6) HIV [11] and
(7) candidemia [12]. Prevalence of fungal disease was calculated based on previously published
epidemiological studies on superficial skin infection, vulvovaginal candidiasis, fungal keratitis,
chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, severe asthma with fungal
sensitization and invasive aspergillosis [13–21]. Recurrent vulvovaginal candidiasis (RVVC) was
defined at 4 or more episodes annually [14]. Data on candidemia was retrieved from the Norwegian
Mycological Reference Laboratory at Oslo University Hospital, as all Candida isolates found in blood
cultures are collected here. Data on infections due to Pneumocystis jirovecii, Cryptococcus ssp., mucorales
and sporadic fungal infections (Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides ssp.,
Paracoccidioides brasiliensis, and Talaromyces marneffei) were collected from the 6 medical microbiological
laboratories in Norway where these infections are diagnosed. They reported their findings on these
specific agents in 2015 answering a form sent to each one and using filtering systems where the
analyses (culture, PCR, antigen-test and immunofluorescence) and agents (P. jirovecii, Mucorales ssp.,




Norway had a population of 5,213,985 as of January 1st 2016 (2,625,111 men), with 21.6% being
under 18 years of age and 10.1% being 70 years of age or older. The number of women between 15
and 50 years of age was 1,235,379 (23.6% of the population). The life expectancy of men and women
was 80.4 and 84.2 years, respectively. The standard of living was high with a gross national product
per capita in 2015 of $74,482 [22]. Education and health care are provided almost free of charge to all
inhabitants, as they are covered through taxes.
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3.2. Superficial Fungal Infections
No data on incidence/prevalence of superficial fungal infections including oral candidiasis,
Candida oesophagitis, RVVC and keratitis, has been reported from Norway. Based on previous
worldwide estimates, a 14.3% incidence of superficial skin disease would result in 745,600
infections/year (Table 1) [13].
Table 1. The burden of fungal disease in Norway in 2015.
* Others: other immunodeficiencies; n.a.: not available.
Based on unpublished data from the largest HIV-clinic in Norway, 9% of the patients were not
receiving anti-retroviral therapy (personal communication from Bente Magny Bergersen, Department
of Internal Medicine, Oslo University Hospital, Oslo, Norway). In 2015, 3,435 patients with HIV
infection lived in Norway. Assuming 20% of untreated patients and 0.5% of treated patients had
esophageal candidiasis (N = 76), and 90% of untreated patients had oral Candida infection (N = 278),
354 HIV patients had Candida in the upper GI-tract (Table 1) [23,24].
Using an estimate of 6% prevalence of RVVC in women aged 15 to 50 years, 74,123 would have
RVVC in 2015 (Table 1) [14]. Based on Danish data from Nielsen et al., a minimum of 0.6 cases per
million of fungal keratitis was estimated, leading to an estimate of 3 cases of fungal keratitis in 2015
(Table 1) [15].
3.3. Respiratory Disease
The prevalence of asthma in the Norwegian population is unknown, but applying the Danish
prevalence of 6.4% of the adult population (N = 261,541) and an estimated 2.5% of these with allergic
bronchopulmonary aspergillosis (ABPA), we had 6,539 asthmatic patients in Norway with ABPA in
2015 (Table 1) [16,25]. In addition, 17.7% of adult patients and 8.2% of children with cystic fibrosis (CF)
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were estimated to have ABPA [18]. In 2015, we had 195 adult and 130 children living with CF, adding
46 patients with ABPA, rendering a total of 6,585 patients (Table 1).
Severe asthma with fungal sensitization (SAFS) is a new and neglected disease. We calculated
estimates based on the number of patients with severe asthma (10% of the total). Estimates have
differed, but in a study by O’Driscoll et al., 43% of patients with severe asthma having SAFS may be a
modest estimate in patients with severe asthma, giving a number of 11,246 patients (Table 1) [21,26].
SAFS is rare in children. Aspergillus bronchitis was estimated in 30% of adult CF patients, rendering
an estimate of 59 patients [18]. Aspergillus bronchitis also occurs in other patients, notably those with
bronchiectasis, but a burden estimate is not possible currently.
Chronic pulmonary aspergillosis (CPA) is usually associated with underlying pulmonary disease.
Globally, tuberculosis is the main underlying cause, but this is a rare infection in Norway today.
The Norwegian Institute of Public Health reported 318 patients with tuberculosis in 2015. Of these, 224
(70%) had pulmonary tuberculosis with a <1% mortality rate. Twenty-seven (12%) were estimated
to have cavitating disease, while 195 did not [17]. Based on data from Denning et al., 22% of
patients with cavitating disease develop CPA and 2% of those without, resulting in 8 patients with
CPA [17]. Approximately 15% will die annually from their CPA, resulting in a 5-year prevalence of 35.
As pulmonary tuberculosis accounts for 16% of CPA cases, this gives a total estimate of prevalence of
219 with CPA (Table 1) [19].
Pneumocystis pneumonia (PCP) was previously associated with HIV infection. In 2015, 221 patients
were diagnosed with HIV in Norway, 11 with AIDS. The total living HIV population amounted
to 3435 patients. An estimate of 4 PCPs among HIV patients was made, based on Danish data
from Thorstensson et al., where 37% of patients with AIDS-defining illness presented with PCP [27].
However, a total of 262 positive P. jirovecii PCRs from 262 patients were registered overall in 2015,
implying non-HIV patients to be more at risk for PCP (Table 1). Data on the correlation to PCP in these
patients was not obtained.
3.4. Invasive Candidiasis and Aspergillosis
Two hundred candidemias were registered in 2015 [12] (Table 1). Assuming the number of
diagnosed candidemias reflects only 50% of the invasive Candida infections, we report a total number
of 400 invasive Candida infections, which includes 43 Candida infections estimated in patients with
hematological malignancies (Table 1) [28]. Invasive Aspergillus (IA) infection was estimated in
transplant recipients, in patients with hematological malignancies and lung cancer based on estimates
according to others (Table 2) [29–32].
Table 2. Estimate of invasive aspergillosis in Norway 2015.
Predisposing Conditions Number of Cases IA * Occurrence % Number of IA
Organ transplantations
Allogeneic HSCT ** 72 10 7
Renal 254 1 3
Liver 86 4 3
Heart 37 6 2
Lung 34 6 2
Pancreas 31 0
Pancreatic Islet cells 5 0
Hematological malignancies 2845 2.9 83
Lung cancer 3125 2.6 81
Severe chronic obstructive
pulmonary disease 7472 admitted 1.3 97
Total 13,961 278
* IA: Invasive Aspergillosis; ** HSCT: Hematopoietic Stem Cell Transplantation.
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In 519 transplant recipients, 17 patients were estimated to have IA (Table 2). In 2845 patients with
hematological malignancies and in 3125 with lung cancer, 83 and 81 patients, were estimated to have
IA, respectively (Table 2). Based on data from others, approximately 1.3% of admitted patients with
severe COPD also developed IA (Table 2) [20,33]. In 2015, 7472 patients were admitted due to COPD,
giving an estimated number of 97 IA patients, resulting in a total of 278 patients with IA.
3.5. Other Fungal Infections
In 2015, mucorales were reported in 7 patients, while Cryptococcus spp. or fungal infections
particular to other geographic regions were not observed (<0.1/100,000).
4. Discussion
In this study, we found that the estimated overall burden of fungal disease in Norway is high,
affecting almost 16 percent of the population. However, excluding superficial skin infections, only
1.79% of the population is affected based on actual numbers from the Microbiological laboratories
and estimates. Invasive infections were not associated with HIV or tuberculosis, but were associated
with other immunocompromising conditions such as cancer, autoimmune diseases or following
organ transplantation.
We do not have data on superficial skin infections and therefore present estimates. We have used
estimates by Vos et al., who predicted a 14.3% prevalence [13]. However, Sigurgeirsson and Baran
report in a review considerably lower numbers of onychomycosis both from population-based and
hospital-based studies from Europe and North America, 4.3% and 8.9%, respectively [34]. In Norway,
nail-infections are expected to be the most common superficial infection. The numbers we present may
therefore be an overestimation of the problem of fungal superficial infections.
Respiratory infections are also a result of estimates, except for data on PCP. Exact numbers
on the prevalence of asthma in the adult population are unknown, which is why we used Danish
data believed to be similar as the basis for both ABPA and SAFS. CPA is more difficult to assess,
as estimates are based on the prevalence of pulmonary tuberculosis, which is rare. CPA may therefore
be underestimated, as COPD and other autoimmune conditions such as sarcoidosis and others may be
more relevant conditions to consider.
Regarding PCP, this is based on data from the 6 Microbiological laboratories which performed
P. jirovecii PCR in Norway in 2015. Mortensen et al. estimates only 1.5/100,000 PCPs from Denmark
in 2013 [35]. From Germany and UK the numbers are even lower, 1.2/100,000 and 0.33–0.93/100,000
respectively [36,37]. From France a national retrospective study using patient records reported an
incidence of 1.5/100,000 [38]. We report 262 PCR-positive cases giving an incidence of 5/100,000.
Carriage among healthy individuals has been reported [39]. It has also been reported from patients
not suspected of having PCP, though a recent study suggests that colonization in patients may in fact
represent a mild disease [40,41]. The PCR method is extremely sensitive. Some of our findings certainly
may represent colonization by the fungus and not clinical infection. However, having been unable
to examine clinical data, we cannot conclude on this matter. While our PCP numbers are probably
too high, we believe other reported numbers may be too low. Based on French data, 41% of PCP was
associated with HIV infection, while 59% had other immunosuppressive diseases [42]. In Norway
only 4 of the 262 P. jirovecii PCR-positive samples were estimated to be from AIDS patients. Even if
only 50% of the total PCR–positive numbers indicated clinical infection, the patients at risk in Norway,
and probably in other western countries, are many. Further studies in this field are needed.
In Norway, candidemia has been followed closely since 1991. The incidence is low (3–4/100,000)
and has been stable for the last years [4]. Assuming that the laboratory-verified candidemia represent
only 50% of the actual invasive Candida infections, we have doubled the number to make a more
accurate estimate of the numbers [28]. Why the incidence in Norway has stayed low is uncertain.
We do see an extensive and increasing use of antifungal drugs, but the use of prophylaxis is reserved
for extreme premature or patients with leukemia or undergoing HSCT or pancreas transplantation [43].
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However, the use of broad-spectrum antibiotics and antibiotics in general is probably more conservative
compared to other countries, due to lower levels of antibiotic resistance. Infection control procedures
are strict and generally well observed. These factors may indeed prevent the establishment of fungal
infections. However, with the demographic shift with an increasing elderly population, and knowing
this patient group represents over 50% of patients with candidemia [1,3,4], we expect these infections
to be on the rise.
Following invasive candidiasis and probably PCP, invasive aspergillosis is believed to be one
of the more “common” invasive fungal diseases in Norway. However, here we lack specific data.
This is partly due to the difficulty in diagnosing this infection, as Aspergillus sp. enters the human body
through the airways, and causes a relatively silent infection. Positive tests may indicate spores that
are being inhaled without implying infection. Whether our estimates are too low or high is difficult
to say, but these infections, though few, are often fatal and expensive, and may be on the rise given
the demographic outlook and more aggressive use of immune-modulating drugs. In 2015 we had 7
cases of invasive mucormycosis. This is a high number, but the incidence is suspected to be on the rise,
probably due to better diagnostics. Though Norwegians are travelling people, there are rarely reports
of particular infections from geographic areas.
This study is part of a global study initiated by Leading International Fungal Education [44],
which has launched the initiative to calculate the fungal burden in countries in order to ascertain the
public health importance of fungal infections and the need to improve diagnostics and treatment.
Estimates have demonstrated that worldwide deaths due to fungal infections (>1,350,000) are as high as
those of tuberculosis (1,400,000) and significantly higher than malaria (445,000) [45,46]. The drawbacks
of the study are several. Diagnostic limitations on reported data are still relevant. Regarding invasive
infections such as candidemia, we can assume both an underdiagnosis and overdiagnosis to occur.
Furthermore, much of the data are estimates, again based on estimates from other countries, and may
not be a precise tally of the actual numbers of these infections in Norway, where the climate is cold,
wealth and educational levels are high and the expected age of living exceeds 80 years for both sexes.
However, even given a low incidence of invasive infections, the morbidity, mortality and economic
costs associated with them warrants better epidemiological data.
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